Pentwater Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Pentwater Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-50,000	Closed	-$622K	–	128
2023 Q2	$622K	Buy	+50,000	New	+$675K	﹤0.01%	113
2021 Q2	–	Sell	-16,100	Closed	-$574K	–	348
2021 Q1	$574K	Sell	16,100 -4,900	-23%	-$162K	0.01%	265
2020 Q4	$589K	Buy	+21,000	New	+$585K	0.01%	191

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Pentwater Capital Management's MRVI Position: Q3 2023 in Review

Pentwater Capital Management sold out of Maravai LifeSciences (MRVI) in Q3 2023, closing a stake of 50,000 shares — an estimated $622K sold.

Pentwater Capital Management first reported a position in MRVI in Q4 2020 and held it in 3 quarters. The position peaked at $622K in Q2 2023. 204 funds tracked by Wall St. Rank hold MRVI as of Q3 2023.

Pentwater Capital Management reported no remaining Maravai LifeSciences position as of Q3 2023 after selling out during the quarter.
Pentwater Capital Management sold 50,000 Maravai LifeSciences shares in Q3 2023, an estimated $622K.
Pentwater Capital Management first reported a position in Maravai LifeSciences in Q4 2020 and held it in 3 quarters.
Pentwater Capital Management's Maravai LifeSciences position peaked at $622K in Q2 2023.
204 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2023.

Based on Pentwater Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.